Connor Clark & Lunn Investment Management Ltd. Has $168,000 Stake in Enanta Pharmaceuticals, Inc. $ENTA

Connor Clark & Lunn Investment Management Ltd. raised its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 23.7% during the first quarter, according to its most recent filing with the SEC. The firm owned 30,465 shares of the biotechnology company’s stock after purchasing an additional 5,829 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.14% of Enanta Pharmaceuticals worth $168,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. US Bancorp DE acquired a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $36,000. Tower Research Capital LLC TRC raised its holdings in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after buying an additional 2,274 shares during the last quarter. GAMMA Investing LLC acquired a new position in Enanta Pharmaceuticals during the first quarter worth $40,000. Squarepoint Ops LLC acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $66,000. Finally, Velan Capital Investment Management LP acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $75,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ENTA shares. HC Wainwright started coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They set a “buy” rating and a $20.00 price objective on the stock. JMP Securities upped their price objective on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 12th. Finally, Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $21.67.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock opened at $8.82 on Thursday. The firm has a 50-day moving average of $7.44 and a 200-day moving average of $6.55. The company has a market cap of $188.57 million, a P/E ratio of -2.04 and a beta of 0.88. Enanta Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $13.43.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.40. The company had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. As a group, research analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.